Fort Sheridan Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.37M Sell
5,314
-10
-0.2% -$10.2K 0.69% 34
2026
Q1
$4.9M Buy
5,324
+246
+5% +$249K 0.59% 37
2025
Q4
$5.46M Buy
5,078
+33
+0.7% +$31.6K 0.69% 29
2025
Q3
$3.85M Buy
5,045
+176
+4% +$131K 0.5% 40
2025
Q2
$3.8M Sell
4,869
-3
-0.1% -$2.33K 0.54% 40
2025
Q1
$4.02M Sell
4,872
-18
-0.4% -$15K 0.61% 35
2024
Q4
$3.77M Buy
4,890
+48
+1% +$39.7K 0.55% 36
2024
Q3
$4.29M Sell
4,842
-26
-0.5% -$23.4K 0.65% 30
2024
Q2
$4.41M Sell
4,868
-19
-0.4% -$15.2K 0.71% 28
2024
Q1
$3.8M Buy
4,887
+3
+0.1% +$2.13K 0.72% 30
2023
Q4
$2.85M Sell
4,884
-227
-4% -$133K 0.57% 34
2023
Q3
$2.75M Sell
5,111
-80
-2% -$41.2K 0.62% 33
2023
Q2
$2.43M Buy
5,191
+2,234
+76% +$937K 0.56% 34
2023
Q1
$1.02M Buy
2,957
+867
+41% +$292K 0.26% 73
2022
Q4
$765K Sell
2,090
-7
-0.3% -$2.48K 0.25% 75
2022
Q3
$678K Sell
2,097
-201
-9% -$63.7K 0.23% 83
2022
Q2
$745K Buy
2,298
+173
+8% +$51.9K 0.24% 76
2022
Q1
$609K Buy
2,125
+33
+2% +$8.49K 0.18% 96
2021
Q4
$578K Buy
2,092
+310
+17% +$78.6K 0.17% 100
2021
Q3
$412K Sell
1,782
-27
-1% -$6.66K 0.13% 114
2021
Q2
$415K Sell
1,809
-43
-2% -$8.64K 0.14% 110
2021
Q1
$346K Buy
1,852
+150
+9% +$29.3K 0.14% 100
2020
Q4
$287K Sell
1,702
-399
-19% -$59.6K 0.14% 98
2020
Q3
$311K Buy
+2,101
New +$325K 0.18% 75

Other funds holding LLY

Fort Sheridan Advisors's LLY Position: Q2 2026 in Review

Fort Sheridan Advisors reduced its Eli Lilly (LLY) stake by 0.19% in Q2 2026, selling an estimated $10.2K and leaving 5,314 shares worth $6.37M. The position accounts for 0.69% of the portfolio, ranked #34.

Fort Sheridan Advisors first reported a position in LLY in Q3 2020 and has held it in 24 quarters since. 4,635 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Fort Sheridan Advisors held 5,314 shares of Eli Lilly worth $6.37M as of Q2 2026.
  • Fort Sheridan Advisors sold 10 Eli Lilly shares in Q2 2026, an estimated $10.2K.
  • Eli Lilly made up 0.69% of Fort Sheridan Advisors's portfolio in Q2 2026, its #34 holding.
  • Fort Sheridan Advisors first reported a position in Eli Lilly in Q3 2020 and has held it in 24 quarters since.
  • 4,635 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Fort Sheridan Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.